Novonesis AS 

$58.43
208
-$0.59-1.01% Today

Statistics

Day High
59.17
Day Low
58.9
52W High
75.85
52W Low
49.9
Volume
1,431
Avg. Volume
75,777
Mkt Cap
0
P/E Ratio
40.38
Dividend Yield
1.73%
Dividend
1.01

Upcoming

Dividends

1.73%Dividend Yield
Apr 26
$0.67
Sep 25
$0.35
Apr 25
$0.61
Sep 24
$0.29
May 24
$0.29
10Y Growth
7.18%
5Y Growth
3.93%
3Y Growth
-10.95%
1Y Growth
5.82%

Earnings

20AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
2.73
4.39
6.05
7.71
Expected EPS
4.904175822095353
Actual EPS
N/A

Financials

7.9%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
4.03BRevenue
318.85MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVZMY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap149.38B
Pfizer is a global pharmaceutical company that competes with Novonesis AS in the development and marketing of medications and vaccines for various diseases, including those in areas where Novonesis may operate.
Merck
MRK
Mkt Cap294.03B
Merck & Co., Inc. is a leading healthcare company that develops innovative pharmaceuticals and vaccines, directly competing with Novonesis AS in several therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson is a diversified healthcare giant that competes with Novonesis AS through its pharmaceutical division, developing drugs that may overlap with Novonesis' product portfolio.
GSK
GSK
Mkt Cap106.31B
GlaxoSmithKline is a global healthcare company that competes with Novonesis AS in the pharmaceutical and healthcare market, particularly in the development of vaccines and medications.
Novartis
NVS
Mkt Cap292.07B
Novartis is a multinational pharmaceutical company that competes with Novonesis AS in researching, developing, manufacturing, and marketing a wide range of healthcare products.
Abbvie
ABBV
Mkt Cap402.35B
AbbVie is a biopharmaceutical company that competes with Novonesis AS in the discovery, development, and commercialization of new medicines and therapies.
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Novonesis AS in the development of prescription pharmaceuticals in several therapeutic areas.
Roche
RHHBY
Mkt Cap332.67B
Roche Holding AG is a healthcare company that competes with Novonesis AS in the pharmaceutical and diagnostics industries, focusing on oncology, immunology, and infectious diseases.
Sanofi
SNY
Mkt Cap105.92B
Sanofi is a global healthcare leader that competes with Novonesis AS in the development and marketing of therapeutic solutions in areas such as rare diseases, multiple sclerosis, and oncology.
Astrazeneca
AZN
Mkt Cap277.22B
AstraZeneca is a global, science-led biopharmaceutical business that competes with Novonesis AS in the discovery, development, and commercialization of prescription medicines, particularly in the oncology sector.

About

Novozymes A/S is a global biotechnology firm that specializes in the creation and distribution of industrial enzymes, microorganisms, and probiotics. Its operational footprint spans across Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific region. The company's broad range of products caters to numerous sectors: Food and Beverages: Supplying ingredients and processing aids for baking, a variety of beverages, dairy production, starch modification, and protein applications. Household Care: Delivering specialized formulations for laundry, dishwashing, and professional cleaning solutions. Agriculture: Providing innovations for crop cultivation, animal health and nutrition, alongside bioyield and biocontrol products for plant growth. Bioenergy and Industrial Processing: Offering critical components for grain and technical processing, encompassing liquefaction, saccharification, fermentation, fiber conversion, and biomass transformation. Textiles: Featuring technologies for biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing. Pulp and Paper: Enhancing processes through fiber modification, bleach boosting, deposit control, starch modification, and deinking agents. Leather Production: Furnishing treatments for acid bating, area expansion, general bating, degreasing, soaking, and unhairing/liming stages. Water and Waste Management: Contributing with bioaugmentation strategies, optimization of biogas production, and sludge management. Pharmaceuticals: Supplying specialized lipases (both free and immobilized), proteases for biocatalysis, and rTrypsin vital for cell culture applications. Furthermore, Novozymes provides offerings related to human health and various protein-based products. Founded in 1925, Novozymes A/S is headquartered in Bagsvaerd, Denmark.
Show more...
CEO
Ms. Ester Baiget
Employees
10582
Country
United States
ISIN
US6701081092

Listings

0 Comments

Share your thoughts

FAQ

What is Novonesis AS stock price today?
The current price of NVZMY is $58.43 USD — it has decreased by -1.01% in the past 24 hours. Watch Novonesis AS stock price performance more closely on the chart.
What is Novonesis AS stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Novonesis AS stocks are traded under the ticker NVZMY.
Is Novonesis AS stock price growing?
NVZMY stock has fallen by -1.03% compared to the previous week, the month change is a -0.27% fall, over the last year Novonesis AS has showed a -22.26% decrease.
When is the next Novonesis AS earnings date?
Novonesis AS is going to release the next earnings report on August 20, 2026.
What were Novonesis AS earnings last quarter?
NVZMY earnings for the last quarter are 0.66 USD per share, whereas the estimation was 0.81 USD resulting in a -17.94% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Novonesis AS revenue for the last year?
Novonesis AS revenue for the last year amounts to 4.03B USD.
What is Novonesis AS net income for the last year?
NVZMY net income for the last year is 318.85M USD.
Does Novonesis AS pay dividends?
Yes, NVZMY dividends are paid semi-annual. The last dividend per share was 0.67 USD. As of today, Dividend Yield (FWD)% is 1.73%.
How many employees does Novonesis AS have?
As of June 16, 2026, the company has 10,582 employees.
In which sector is Novonesis AS located?
Novonesis AS operates in the Materials sector.
When did Novonesis AS complete a stock split?
Novonesis AS has not had any recent stock splits.
Where is Novonesis AS headquartered?
Novonesis AS is headquartered in Lyngby, United States.